Mücke Victoria, Mücke Marcus M, Raine Tim, Bettenworth Dominik
Department of Internal Medicine 1, J.W. Goethe University Hospital, Frankfurt, Germany (Victoria Mücke, Marcus M. Mücke).
Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK (Tim Raine).
Ann Gastroenterol. 2017;30(1):15-22. doi: 10.20524/aog.2016.0083. Epub 2016 Sep 6.
Anemia represents one of the most frequent complications in inflammatory bowel disease (IBD) and severely impairs the quality of life of affected patients. The etiology of anemia in IBD patients can be multifactorial, often involving a combination of iron deficiency (ID) and anemia of chronic disease (ACD). Although current guidelines recommend screening for and treatment of anemia in IBD patients, current observational data suggest that it still remains underdiagnosed and undertreated. Besides basic laboratory parameters (e.g. mean corpuscular volume, reticulocyte count, serum ferritin, transferrin saturation, etc.), the concentration of soluble transferrin receptor (sTfR) and novel parameters such as the sTfR/log ferritin index can guide the challenging task of differentiating between ID and ACD. Once identified, causes of anemia should be treated accordingly. This review summarizes our current understanding of anemia in IBD patients, including the underlying pathology, diagnostic approaches and appropriate anemia treatment regimens.
贫血是炎症性肠病(IBD)最常见的并发症之一,严重损害了受影响患者的生活质量。IBD患者贫血的病因可能是多因素的,通常涉及缺铁(ID)和慢性病贫血(ACD)的综合作用。尽管当前指南建议对IBD患者进行贫血筛查和治疗,但目前的观察数据表明,贫血仍未得到充分诊断和治疗。除了基本实验室参数(如平均红细胞体积、网织红细胞计数、血清铁蛋白、转铁蛋白饱和度等)外,可溶性转铁蛋白受体(sTfR)的浓度以及诸如sTfR/铁蛋白对数指数等新参数可以指导区分ID和ACD这一具有挑战性的任务。一旦确定贫血原因,就应相应地进行治疗。本综述总结了我们目前对IBD患者贫血的认识,包括潜在病理、诊断方法和适当的贫血治疗方案。